Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2017-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2017-04-28 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is announcing the completion of enrollment in clinical trials and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is it an annual or quarterly report. The document is short (2349 characters) and primarily serves as an announcement of an event rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-04-24 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 4, 2017, by Lipocine Inc. It announces the company's participation in the 16th Annual Needham Healthcare Conference and attaches presentation materials as Exhibit 99.1. The content focuses on investor presentation materials rather than financial statements or detailed financial analysis. The document length is 2292 characters, which is relatively short and primarily serves as an announcement of the presentation and its materials. Therefore, it fits best under the category of Investor Presentation (IP).
2017-04-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2017, by Lipocine Inc. It announces that the company will be presenting at the 29th Annual Roth Conference and that presentation materials are attached as Exhibit 99.1. The document is short (2272 characters) and primarily serves as an announcement of the presentation and the availability of materials, rather than containing the full presentation or detailed financial data itself. This fits the description of an Investor Presentation announcement within an 8-K filing. However, since the document itself is the 8-K current report announcing the presentation and attaching the materials, and not the presentation itself, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full investor presentation or detailed financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-03-13 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a controlled equity offering of common stock. It details the terms of the offering, the sales agreement with Cantor Fitzgerald, risk factors, use of proceeds, and other related information. This type of document is a capital raising disclosure, specifically describing a financing activity involving the issuance of new shares. It is not an annual or quarterly report, audit report, management discussion, or any other type of report. It is clearly an update on capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a full prospectus supplement, supporting high confidence.
2017-03-06 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 6, 2017. It reports the entry into a Controlled Equity Offering Sales Agreement and references the Annual Report on Form 10-K filed on the same date. The document includes legal opinions as exhibits and does not contain detailed financial statements or substantive financial data itself. The length is 3831 characters, which is relatively short and the document primarily announces a financing agreement and related legal opinions. According to the rules, such a document is an announcement of a financing activity rather than the financing report itself. Therefore, it fits best under Capital/Financing Update (CAP).
2017-03-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.